A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Erdafitinib (Primary)
- Indications Breast cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 08 Feb 2019 Planned End Date changed from 31 Dec 2019 to 22 Apr 2020.
- 08 Feb 2019 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 Planned initiation date changed from 12 Nov 2018 to 6 Dec 2018.